E-LIB Suche - Ergebnisse für: Fayette, J

1

Durvalumab with or without tremelimumab versus the EXTREME ..:

Psyrri, A. ; Fayette, J. ; Harrington, K....
Annals of Oncology. 34 (2023) 3 - p. 262-274 , 2023

Link: https://doi.org/10.1016/..

2

PCR132 Correlation Between Quality of Life (QoL) of Patient..:

Baumstarck, K. ; Even, C. ; Grumberg, V....
Value in Health. 26 (2023) 12 - p. S474 , 2023

Link: https://doi.org/10.1016/..

3

Fission products at the fuel-cladding interface of PWR fuel..:

Schneider, C. ; Fayette, L. ; Zacharie-Aubrun, I....
Journal of Nuclear Materials. 585 (2023) - p. 154600 , 2023

Link: https://doi.org/10.1016/..

4

Study of the hardness and Young's modulus at the fuel-cladd..:

Schneider, C. ; Fayette, L. ; Zacharie-Aubrun, I....
Journal of Nuclear Materials. 560 (2022) - p. 153511 , 2022

Link: https://doi.org/10.1016/..

5

Microstructural Analysis of Zirconia at the Fuel-Cladding I..:

Schneider, C. ; Fayette, L. ; Zacharie-Aubrun, I....
Oxidation of Metals. 96 (2021) 3-4 - p. 295-306 , 2021

Link: https://doi.org/10.1007/..

6

Immune checkpoint inhibitor treatment of a first cancer is ..:

Heudel, P. ; Chabaud, S. ; Perol, D....
ESMO Open. 6 (2021) 1 - p. 100044 , 2021

Link: https://doi.org/10.1016/..

7

A randomized phase II study comparing the efficacy and safe..:

Klinghammer, K. ; Fayette, J. ; Kawecki, A....
ESMO Open. 6 (2021) 5 - p. 100242 , 2021

Link: https://doi.org/10.1016/..

8

MOX fuel microstructural evolution during the VERDON-3 and ..:

Le Gall, C. ; Reboul, S. ; Fayette, L....
Journal of Nuclear Materials. 531 (2020) - p. 152015 , 2020

Link: https://doi.org/10.1016/..

9

A phase 1b trial of prexasertib in combination with chemora..:

Yang, E.S. ; Deutsch, E. ; Mehmet, A....
International Journal of Radiation Oncology*Biology*Physics. 106 (2020) 5 - p. 1136 , 2020

Link: https://doi.org/10.1016/..

10

Durvalumab with or without tremelimumab in patients with re..:

Ferris, R.L. ; Haddad, R. ; Even, C....
Annals of Oncology. 31 (2020) 7 - p. 942-950 , 2020

Link: https://doi.org/10.1016/..

11

Fission product speciation in the VERDON-3 and VERDON-4 MOX..:

Le Gall, C. ; Reboul, S. ; Fayette, L....
Journal of Nuclear Materials. 530 (2020) - p. 151948 , 2020

Link: https://doi.org/10.1016/..

12

COGNITIVE IMPAIRMENT AFTER 6 AND 12 MONTHS OF HODGKIN LYMPH..:

Mocikova, H. ; Gaherova, L. ; Fayette, D....
Hematological Oncology. 37 (2019) S2 - p. 498-499 , 2019

Link: https://doi.org/10.1002/..

13

Two-year Update From CheckMate 141: Outcomes With Nivolumab..:

Ferris, R.L. ; Blumenschein, G.R. ; Fayette, J....
International Journal of Radiation Oncology*Biology*Physics. 100 (2018) 5 - p. 1317 , 2018

Link: https://doi.org/10.1016/..

14

A Randomized, Open-Label, Multicenter, Global Phase 2 Study..:

Siu, L. ; Even, C. ; Mesía, R....
International Journal of Radiation Oncology*Biology*Physics. 100 (2018) 5 - p. 1307 , 2018

Link: https://doi.org/10.1016/..

15

PO-147: The ELAN program: Customised treatment of SCCHN eld..:

Guigay (France), J. ; Ortholan, C. ; Le Caer, H....
Radiotherapy and Oncology. 122 (2017) - p. 70-71 , 2017

Link: https://doi.org/10.1016/..